Skip to main content
Monday, November 16, 2026Nov 16

Study hints antibody drug may cut COVID-19 hospitalizations

In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. On Wednesday, Sept. 16, 2020, Lilly said that partial results from a study testing an antibody drug in mild to moderately ill COVID-19 patients give hints that the drug may help keep them from needing to be hospitalized. But the results have not been published or reviewed by independent scientists. (David Morrison/Eli Lilly via AP)
In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. On Wednesday, Sept. 16, 2020, Lilly said that partial results from a study testing an antibody drug in mild to moderately ill COVID-19 patients give hints that the drug may help keep them from needing to be hospitalized. But the results have not been published or reviewed by independent scientists. (David Morrison/Eli Lilly via AP)

A drug company says that partial results from a study testing an antibody drug give hints that it may help keep mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet.

Eli Lilly announced the results Wednesday in a press release, but they have not been published or reviewed by independent scientists.

The drug missed the study’s main goal of reducing the amount of virus patients had after 11 days, except at the middle of three doses being tested. However, most study participants, even those given a placebo treatment, had cleared the virus by then, so that time point now seems too late to judge that potential benefit, the company said.

Other tests suggest the drug was reducing virus sooner, and the results are an encouraging “proof of principle” as this and other studies continue, Lilly said.

The company said it would talk with regulators about possible next steps but that it was too soon to speculate on whether these interim results might lead to any action to allow early use.